Articles related to ALZHEIMER'S/DEMENTIA

Phase 2a clinical trials demonstrate benfotiamine’s ability to enhance synaptic activity while maintaining an excellent safety profile, even at doses exceeding normal thiamine blood levels.

Nearly half of behavioral variant frontotemporal dementia patients initially receive a psychiatric diagnosis, highlighting the critical need for improved diagnostic approaches.

Risk of dementia with these medications increases proportionally with higher doses and extended duration of use, emphasizing the importance of minimal effective dosing strategies.

This comprehensive overview of dementia symptoms provides physicians with a practical framework for patient education and early detection. By recognizing these signs early, healthcare providers can initiate timely interventions and support strategies to enhance patient care.

Recent research comparing SGLT2 inhibitors and dulaglutide in older patients with type 2 diabetes suggests a potential difference in dementia risk. The study estimated a risk ratio of 0.81 (CI, 0.56 to 1.16) for SGLT2 inhibitors compared to dulaglutide.

Changes to blood-based biomarkers can be detected before Alzheimer’s symptoms appear, potentially allowing for earlier intervention and more targeted treatment approaches.